bottom line underweight rate reflect
view see downsid pressur street sale earn
forecast believ ilmn report result well-below-
street guidanc support view
sale beat didnt right driver ilmn sale beat
reli one-tim payment roch upsid vs street
estim consum genom purchas
unsustain fact ilmn disclosur suggest expect
consum genom sale fall nearli sequenc
instrument sale fell short street assumpt forecast
guid wors contempl even back-
end load adjust downward forecast
reflect linear similar compani guidanc
sale well wors forecast street
season sequenc instrument consum
like sever model previous consum
genom also wors bright side consum genom
becom increasingli less materi like exit
compani total
stori hing adopt product clinic applic
sequenc consum diagnost grew strong
rate nonetheless meaning deceler
contempl model
growth applic oncolog import ilmn
driver grew impact coronaviru could pressur
ilmn growth rate china though compani
opportun contribut public health side
instrument audit show greater cannib
contempl ilmn downwardli revis hiseq instal base
instrument year-end year-end
evidenc instrument cannib previous
contempl compani current revisit instal base
disclosur mid low throughput instrument well
would expect downward revis product plu
side suggest consum util per instrument across
ilmn portfolio higher previous model
novaseq consum pull-through per instrument
compani expect could hold nearli steadi
despit lower util increment custom
model updat reduc estim
 note herein result
reduc target price unchang
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
exclud amort acquir intang non-cash interest one-tim item
 iprd write-off comput non-gaap dilut sharecount
compani data secur llc estim reuter
period end expens net incom attribut non-control incom attribut ep dilut share share alreadi ex amort cash flowoper cash cash ep incl exclud amort acquir intang non-cash interest one-tim item iprd write-off comput non-gaap dilut sharecountsourc secur llc estim compani report inc
price target
price target reflect price-to-earnings ratio earn estim multipl
discount median peer group open-end growth stock healthcar believ
appropri given current growth challeng upsid risk underweight rate includ
limit follow factor first faster larger contribut popul sequenc
program model would provid potenti upsid compar estim well
market see faster adopt diagnost greater forecast rebound china
faster ramp consum growth gener could see investor appetit name
increas could see downsid risk continu pattern downward guidanc revis
investor becom disillus stori
underweight rate reflect view see downsid pressur street sale
earn forecast
san diego california-bas inc develop manufactur market
life scienc tool use genom compani technolog encompass two major type system
microarray next gener sequenc via novaseq hiseq nextseq miseq miniseq
platform half compani revenu come consum use variou
platform follow instrument system servic outsourc sequenc genotyp
servic well servic contract product custom includ genom research center
compani agrigenom compani consum genom compani
